Peptide Therapy Basics: What the Published Research Shows
Peptide therapy explained from published research. Compounds studied, protocols used in clinical settings and the 2026 regulatory landscape.
The phrase peptide therapy has come into use among research scientists, doctors, and patients, but it bears a different meaning in each context. In this guide you will find out what existing studies say about therapeutic peptides, which substances have been studied the best and what the current legal situation is as of the year 2026.
What Peptide Therapy Means in a Research Context
Endogenous vs Synthetic Peptides
Countless peptides are produced by the human body to serve as signaling molecules; for example, well-known endogenous peptides such as insulin, oxytocin, GLP-1 and growth hormone releasing hormone perform their own specific physiological functions. At the same time, there are synthetic peptides developed in laboratories, such as BPC-157 and Epithalon, that are made to imitate, modify and expand the natural signaling functions of the peptides produced by our bodies. This points to the significance of the difference above, as the regulations governing synthetic peptides, alongside safety and clinical data, are not the same for the long-time used endogenous peptides produced by the body.
Why Peptides Are Not Small Molecules
Common medications such as aspirin and ibuprofen are examples of small molecules, which generally have molecular weights of below 500 daltons. Peptides belong to a size category between small molecules and complete proteins, usually containing 2-50 amino acids and having molecular weights in the range of about 500-5,000 daltons. Such intermediate size characteristics grant peptides different pharmacological properties - while peptides are more selective than small molecules, they are also less stable in the gastrointestinal tract and blood stream; hence they are usually administered through injection.
- 2-50
- amino acid range that defines a peptide
- 500-5000
- typical molecular weight range in daltons
- 3
- primary routes of administration: SC injection, nasal, oral
Peptides Studied in Clinical and Preclinical Settings
Tissue Repair Peptides
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a protein found in human gastric juice. It has been studied in over 100 published animal experiments for effects on tendon, muscle, bone and gastrointestinal tissue repair. TB-500, a fragment of Thymosin Beta-4, has preclinical data on wound healing and inflammation. Neither has completed human clinical trials for tissue repair indications, according to a 2018 review in Current Pharmaceutical Design.
Growth Hormone Secretagogues
Ipamorelin, CJC-1295, and Tesamorelin are all peptides that increase the activity of the pituitary gland and lead to the production of growth hormone in the body. Tesamorelin is FDA-approved for treating lipodystrophy related to HIV but both Ipamorelin and CJC-1295 are still considered investigational drugs. Studies are focused on growth hormone secretagogues and their various effects on body composition, bone density, and metabolic parameters.
Mitochondrial and Metabolic Peptides
MOTS-c is a mitochondrial-derived peptide studied for its effects on insulin sensitivity, exercise capacity and metabolic regulation. Epithalon (Epitalon) is a synthetic tetrapeptide analog of Epithalamin, studied for telomerase activation in cell and animal models. A 2018 study published in Cell Metabolism demonstrated MOTS-c effects on exercise performance in mice.
Neuropeptides and Nootropics
Semax and Selank are synthetic peptide series first developed and used in Russia for medical purposes. Semax is regarded as being a synthetic analog of ACTH(4-10) and was studied for various neuroprotective and memory enhancing properties. On the other hand, Selank is a synthetic analog of Tuftsin. In both cases the administration route is nasal. The scientific literature reports changes in the level of BDNF and behavior similar to anxiety.
| Peptide | Amino Acids | Route | Research Stage | Category |
|---|---|---|---|---|
| BPC-157 | 15 | SC injection / oral | Preclinical (100+ studies) | Recovery |
| TB-500 | 43 | SC injection | Preclinical | Recovery |
| Ipamorelin | 5 | SC injection | Phase II clinical | Growth Hormone |
| Epithalon | 4 | SC injection | Preclinical + limited human | Longevity |
| Semax | 7 | Nasal spray | Approved in Russia; preclinical elsewhere | Cognitive |
How Peptide Protocols Appear in Published Studies
Dosing by Body Weight in Animal Models
Peptide doses in animal experiments are often calculated in micrograms per kilogram of body weight (mcg/kg). As per a report in a 2010 study on tendon healing in the Journal of Orthopaedic Research, various studies with rats using BPC-157 use a dose of 10 mcg/kg by the subcutaneous and intraperitoneal route. These doses of the drug cannot be compared to humans unless necessary allometric scaling and clinical validation is performed.
Duration and Cycling in Research Designs
The majority of the studies conducted on BPC-157 have lasted between 14 days and 72 days using animal models. Meanwhile, studies using growth hormone secretagogues have often lasted for a period of 8 weeks to 12 weeks. Studies with Epithalon have done protocols with animals for 10 consecutive days repeated over several months. There is no protocol in cycling the research peptides as there is a lack of long-term data involving humans other than the approved indication of Tesamorelin.
The Regulatory Landscape for Peptides in 2026
FDA Classification and Compounding Rules
The FDA does not recognize research peptides as drugs with marketing approval. A huge number of peptides available on the web today are sold under the names of "research chemicals" or "for research purposes only". In 2023, due to the issuance of new guidance on bulk drug products used for compounding by the FDA the access to different peptides via compounding pharmacies was limited. In 2024, the guidance underwent further changes, and several new compounds were disclosed and many compounds previously on the list were excluded.
Research-Use-Only vs Prescription Peptides
The peptide known as Tesamorelin, also known by its commercial name Egrifta, is a medication that can be dispensed only under a prescription from the FDA. The peptide Semaglutide (market names Ozempic and Wegovy) along with tirzepatide (market names Mounjaro and Zepbound) belong to the group of drugs known as GLP-1 receptor agonists. Although they are technically peptides, they are classified as different drugs. All other peptides that we talk about on this site are being sold in the USA as research chemicals without being accepted for human use by the FDA.
- 2019: FDA issues warning letters to companies marketing peptides as treatments
- 2020: Category 2 bulk drug substance list updated for compounding pharmacies
- 2023: FDA publishes revised guidance on bulk compounding substances; several peptides removed from permitted list
- 2024: Final rule on compounding bulk drug substances published; BPC-157 remains in a regulatory gray area for compounding
- 2026: Market continues to bifurcate into research-use suppliers and licensed compounding pharmacies
Limitations of Current Peptide Research
Most Data Comes from Animal Models
The bulk of published literature on BPC-157, TB-500, Epithalon and MOTS-c is derived from experiments conducted on rats, mice and cell cultures. Findings from animals are not necessarily relevant for humans. Differences in metabolism, immune response and body composition mean that a treatment that yields beneficial results on a rat does not automatically mean the same result would be seen in humans.
Human Trial Gaps
As of this time, there have been no clinical trials in humans which have been published and completed for BPC-157 in terms of tissue repair. Ipamorelin is available for Phase II data but has received no approvals for Phase III. For MOTS-c there is already early clinical data on its influence on exercise metabolism. The principal flaw in the current evidence base is that, while there has been a considerable amount of animal research done, there is a lack of research done in humans.
FAQ, Peptide Therapy
Is peptide therapy FDA-approved?
Only a few specific peptide drugs have been approved by the FDA for certain indications, including Tesamorelin for HIV-related lipodystrophy and semaglutide for diabetes and weight loss management. The term "peptide therapy" is commonly used in the context of wellness for naming research peptides which are not approved by the FDA for any medical use.
What is the difference between research peptides and prescription peptides?
Research peptides are chemical compounds used in laboratories and are not authorized by the FDA for use in humans. Prescription peptides are produced under cGMP guidelines and are approved by the FDA for various medical conditions; they are distributed through licensed pharmacies having a doctor’s prescription.
Can peptides replace conventional treatments?
There is no proof in literature regarding the role of research peptides as substitutes for traditional therapy methods. All peptides mentioned on this website are classified as research peptides and do not claim to possess therapeutic qualities when used on human subjects.
How are peptides administered in research?
The routes most frequently reported in published research are subcutaneous injection, intraperitoneal injection, nasal spray, and oral administration. Subcutaneous injection refers to the injection just beneath the skin, whilst the intraperitoneal route is primarily used in rodents. The nasal spray method of administration is used mainly for neuropeptides like Semax and Selank, while oral administration has been studied with BPC-157 capsules and different modified peptides. More information about these routes can be found in injectable peptides guide and oral peptides guide.
Compare the current picks
Prices, sizes and ratings side by side, updated when the merchant pages change.
Shop peptides